Episode description
Episode description
Join us for a captivating interview with our guest Professor Carl June, Director of the Centre for Cellular Immunotherapies at the University of Pennsylvania, USA, as he discusses the current directions in CAR T-cell therapy.
Together with our host Dr. Sarah de Vlieger, they examine the latest results on both pediatric and adult patients with over ten years of follow up. They cover ongoing trials aimed at drastically reducing the vein-to-vein time for autologous CAR T-cells, as well as trends toward academic manufacturing and the full automation of production processes.
Finally, Prof. June provides insight into USA FDA’s warning about secondary malignancies in CAR T-cell-treated patients issued in November 2023.
Host: Sarah de Vlieger, EHA Head of Education
Guest: Prof Carl June
This is the first of a series of podcasts recorded at the 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe